Blood Transfusion Diagnostics Market Overview
The Blood Transfusion Diagnostics Market is expanding as healthcare systems strengthen blood safety standards, surgical and trauma procedures increase, and blood banks adopt automated screening and typing technologies. Growing adoption of nucleic acid testing, pathogen-reduction technologies, digital blood-bank systems, and advanced blood-group testing is creating new opportunities for diagnostic manufacturers and technology providers.
According to the Market Research Future report updated August 24, 2026, the global Blood Transfusion Diagnostics Market stood at USD 6.52 billion in 2025 and is projected to reach USD 6.96 billion in 2026 and USD 12.49 billion by 2035, registering a CAGR of 6.72% during the forecast period 2025–2035. North America led the market with approximately 38% of revenue in 2025, followed by Europe at around 28%, while Asia-Pacific is the fastest-growing region with an estimated CAGR of 8.4%. Consumables accounted for more than 62% of the product market, while Instruments are expanding at the fastest segment CAGR of 7.8%. Serology remained the dominant technology with approximately USD 4.1 billion in 2025 revenue, whereas Nucleic Acid Tests are the fastest-growing technology at an 8.3% CAGR. Disease Screening held approximately 55% of application revenue, while Blood Group Typing is projected to grow at 7.4% CAGR. Hospitals represented 45% of end-user revenue, while Diagnostic Laboratories accounted for USD 2.48 billion in 2025.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
Key players driving innovation and competitiveness in the Blood Transfusion Diagnostics Market include:
Grifols S.A.
Bio-Rad Laboratories
QuidelOrtho
Immucor (Werfen)
Quotient Limited
Beckman Coulter (Danaher)
BAG Healthcare
DiaSorin S.p.A.
Hemosonics (Stago)
Agena Biosciences (Bruker)
The Blood Transfusion Diagnostics Market is being reshaped by the transition from labor-intensive manual testing toward automated column-agglutination, solid-phase, and molecular testing platforms. Regulatory requirements for pathogen screening are encouraging blood centers to adopt individual-donor NAT, while connected laboratory systems are improving traceability and digital audit capabilities. Reagent-rental models are also lowering upfront capital barriers for hospitals, allowing manufacturers to secure recurring consumable revenue while enabling facilities to modernize their diagnostic infrastructure.
The Blood Transfusion Diagnostics Market can be segmented by Product Type, Technology, Application, End User, and Region. By product type, Consumables dominate with more than 62% share because blood banks require recurring reagents, test cards, and assay kits, while Instruments are the fastest-growing category at 7.8% CAGR. By technology, Serology remains the largest segment at approximately USD 4.1 billion in 2025, while Nucleic Acid Tests are growing fastest at 8.3% CAGR. By application, Disease Screening leads with 55% share, while Blood Group Typing is projected to grow at 7.4% CAGR. By end user, Hospitals hold 45% share, while Diagnostic Laboratories represent a major centralized testing market. Regionally, North America leads, Europe remains the second-largest market, and Asia-Pacific is the fastest-growing region.
Significant opportunities are emerging from point-of-care blood-typing devices, AI-driven antibody identification, molecular blood-group genotyping, emerging-market blood-bank modernization, and digital hemovigilance platforms. Handheld and cartridge-based testing can expand access to rapid blood typing in emergency and remote settings, while AI-assisted antibody identification can reduce complex laboratory workflows. The modernization of blood banks across South Asia and Africa also presents substantial opportunities for automated screening systems, reagents, instruments, and connected laboratory platforms.
Recent Developments and Market Trends:
Automated blood-bank platforms are replacing manual tube testing as healthcare providers seek faster turnaround times, improved standardization, and reduced laboratory error.
Nucleic acid testing is gaining momentum as individual-donor screening requirements strengthen detection of HIV, HBV, HCV, and other transfusion-transmitted infections.
AI-assisted antibody identification and inventory optimization are emerging as important technologies for reducing technologist workload and improving transfusion safety.
Molecular blood-group genotyping and extended antigen profiling are expanding beyond specialized laboratories as sequencing costs decline and precision transfusion practices gain adoption.
Emerging markets across Asia-Pacific, Africa, and South America are investing in blood-bank modernization, voluntary donation programs, automation, and improved transfusion-safety infrastructure.
Reasons to Buy the Report:
Understand the projected expansion of the Blood Transfusion Diagnostics Market from USD 6.52 billion in 2025 to USD 12.49 billion by 2035.
Evaluate the competitive landscape and strategic positioning of leading blood-transfusion diagnostic manufacturers and technology providers.
Identify the dominant and fastest-growing product, technology, application, end-user, and regional market segments.
Assess the impact of automation, NAT adoption, regulatory requirements, pathogen reduction, and blood-bank modernization.
Gain strategic insights into AI-enabled diagnostics, molecular genotyping, point-of-care testing, reagent-rental models, and emerging-market opportunities.
Future Outlook:
The Blood Transfusion Diagnostics Market is expected to maintain steady growth through 2035 as rising surgical and trauma volumes, stricter blood-safety regulations, expanding voluntary blood-donation programs, and blood-bank modernization increase demand for reliable diagnostic technologies. Consumables will remain the dominant product category with more than 62% share because reagents, test cards, and NAT kits generate recurring demand across blood banks, while Instruments are expected to grow fastest at 7.8% CAGR as hospitals replace aging manual systems with automated analyzers. Serology will continue to represent the largest technology segment with approximately USD 4.1 billion in 2025 revenue because it remains fundamental to ABO/Rh typing, antibody screening, and compatibility testing, while Nucleic Acid Tests are projected to be the fastest-growing technology at 8.3% CAGR as individual-donor NAT requirements expand. Disease Screening will remain the leading application with 55% share, supported by mandatory testing for transfusion-transmitted infections, while Blood Group Typing is expected to grow rapidly at 7.4% CAGR as extended phenotyping and genotyping become more widely adopted. Hospitals will remain the largest end-user segment with 45% share, while Diagnostic Laboratories will continue to play a critical role in centralized and high-volume testing. North America will retain its leadership with approximately 38% of market revenue in 2025, followed by Europe at 28%, while Asia-Pacific will remain the fastest-growing region at an estimated 8.4% CAGR because of expanding blood-bank infrastructure and rising healthcare investment in China, India, Japan, and other regional markets. Automation, AI-assisted antibody identification, molecular blood-group testing, point-of-care diagnostics, digital hemovigilance, and pathogen-screening technologies are expected to further transform the industry and support the Blood Transfusion Diagnostics Market in reaching USD 12.49 billion by 2035.
➤➤Explore Our Latest Related Reports:
